Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors (vol 10, pg 1, 2018)

被引：0
|
作者：
Hirsh, V
机构：
来源：
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2018年 / 10卷
关键词：
D O I：
10.1177/1758835918769391
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors
    Hirsh, Vera
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [2] EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations
    Kim, Edward S.
    Melosky, Barbara
    Park, Keunchil
    Yamamoto, Nobuyuki
    Yang, James C-H
    [J]. FUTURE ONCOLOGY, 2021, 17 (18) : 2395 - 2408
  • [3] Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations
    Shah, Riyaz
    Lester, Jason F.
    [J]. CLINICAL LUNG CANCER, 2020, 21 (03) : E216 - E228
  • [4] EGFR Tyrosine Kinase Inhibitor and Chemotherapy in EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Nishino, Kazumi
    Kimura, Madoka
    Inoue, Takako
    Uchida, Junji
    Kumagai, Toru
    Imamura, Fumio
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S526 - S526
  • [5] Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer
    Bridges, John F. P.
    de la Cruz, Marie
    Pavilack, Melissa
    Flood, Emuella
    Janssen, Ellen M.
    Chehab, Nabil
    Fernandes, Ancilla W.
    [J]. FUTURE ONCOLOGY, 2019, 15 (34) : 3895 - 3907
  • [6] First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis
    Holleman, Marscha S.
    van Tinteren, Harm
    Groen, Harry J. M.
    Al, Maiwenn J.
    Uyl-de Groot, Carin A.
    [J]. ONCOTARGETS AND THERAPY, 2019, 12 : 1413 - 1421
  • [7] EGFR tyrosine kinase inhibitors as first-line therapy in advanced EGFR mutation-positive non-small cell lung cancer: strategies to improve clinical outcome
    Tiefenbacher, Andreas
    Pirker, Robert
    [J]. JOURNAL OF THORACIC DISEASE, 2017, 9 (11) : 4208 - 4211
  • [8] EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer
    Kamel-Reid, S.
    Chong, G.
    Ionescu, D. N.
    Magliocco, A. M.
    Spatz, A.
    Tsao, M.
    Weng, X.
    Young, S.
    Zhang, T.
    Soulieres, D.
    [J]. CURRENT ONCOLOGY, 2012, 19 (02) : E67 - E74
  • [9] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Stinchcombe, Thomas E.
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (04)
  • [10] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Thomas E. Stinchcombe
    [J]. Current Treatment Options in Oncology, 2016, 17
12345